Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Addex Therapeutics initiates at-the-market offering program

EditorNatashya Angelica
Published 01/31/2024, 01:08 AM
Updated 01/31/2024, 01:08 AM
© Reuters.

GENEVA - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company, has announced the establishment of an at-the-market (ATM) offering program. Through this arrangement with H.C. Wainwright & Co., LLC, Addex may periodically sell American Depositary Shares (ADSs) up to a total of $2.1 million.

This sales agreement leverages the company's effective registration statement on Form F-3 and allows H.C. Wainwright to sell the ADSs on various trading markets, including The Nasdaq Capital Market. The transactions will adhere to legal requirements and could be subject to company-imposed conditions such as price and volume limits.

Under the terms of the agreement, H.C. Wainwright will receive a 3% commission on the gross proceeds from the sales of ADSs. Both Addex and H.C. Wainwright retain the right to suspend or terminate the offering upon notice, subject to certain conditions.

Addex emphasizes that this press release does not constitute an offer to sell or a solicitation of an offer to buy these securities. Furthermore, no sales under the ATM will be conducted in Switzerland.

The company is engaged in developing allosteric modulators for neurological disorders, a new class of small molecule drugs. Addex's lead drug candidate, ADX71149, is undergoing a Phase 2 clinical trial for epilepsy treatment. Its second clinical program, dipraglurant, is being evaluated for potential development in post-stroke recovery. Additionally, Addex has licensed its GABAB PAM program to Indivior PLC, focusing on substance use disorder.

The company also has a preclinical pipeline that includes treatments for chronic cough, stress-related disorders, schizophrenia, psychosis, mild neurocognitive disorders, and depression.

The details of the ATM Agreement outlined in this announcement are not exhaustive and are fully described in the agreement's full text, which is referenced for complete information.

This news is based on a press release statement from Addex Therapeutics. The company's shares are traded on the SIX Swiss Exchange and the NASDAQ Capital Market under the ticker symbol ADXN.

InvestingPro Insights

In light of Addex Therapeutics' recent announcement regarding their ATM offering program, insights from InvestingPro shed light on the company's financial health and market performance. Addex Therapeutics holds more cash than debt on its balance sheet, providing a measure of financial stability. However, analysts at InvestingPro have flagged concerns such as the company's rapid cash burn and weak gross profit margins. This is particularly relevant as the company embarks on new financing ventures. Additionally, the stock has been identified as being in overbought territory according to the RSI, which could suggest a potential retraction in the near future.

From a market perspective, Addex's stock has seen a significant return over the last week, month, and three months, with a 25.66%, 79.67%, and 72.81% price total return respectively. Despite this recent uptick, the company's year-to-date price total return stands at 79.67%, indicating a strong performance since the beginning of the year.

InvestingPro data highlights a market capitalization of $12.61M USD for Addex, with a notably high revenue growth of 65.32% in the last twelve months as of Q3 2023. Nonetheless, the company's gross profit margin during the same period was -275.12%, emphasizing the challenges it faces in translating revenue growth into profitability.

For readers interested in a deeper analysis, InvestingPro offers additional tips on Addex Therapeutics, which can be found at The InvestingPro subscription is currently on a special New Year sale with a discount of up to 50%. Use coupon code SFY24 to get an additional 10% off a 2-year InvestingPro+ subscription, or SFY241 to get an additional 10% off a 1-year InvestingPro+ subscription. There are many more InvestingPro Tips available to help investors make informed decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.